To assess the antitumor efficacy of M28z, MBBz and M1xx CAR T cells in an in vivo model, NSG mice were inoculated with MSLN+GFP+/ffLuc+ SKOV-3 cells (figure 2A), followed by M28z, MBBz or M1xx CAR T cell intravenous treatment 21 days post tumor engraftment. This evidence concerns the gene MSLN and neoplasm.